PLCβ1 modulation is clinically relevant in leukemogenesis of MDS, as its mono-allelic deletion is associated with increased risk of AML progression and its expression is inversely correlated with AKT/ mTOR activation in higher-risk MDS (39–42). Here, MTOR is linked to acute myeloid leukemia.